Loading
A majority of people of West African ancestry carry the Duffy-null variant, which lowers baseline neutrophil counts without raising infection risk. Trials apply a single neutrophil cut-off that wrongly labels them unfit, so protocols should use Duffy-specific thresholds; Duffy status is a cheap blood test.
The Duffy-null phenotype (ACKR1 rs2814778 CC), carried by a majority of people of West African ancestry, is associated with lower baseline neutrophil counts without increased infection risk. Protocols would use Duffy-status-specific absolute neutrophil count thresholds (or exclude on infection history rather than ANC alone), and dose-modification rules for neutropenia would be reinterpreted accordingly. Duffy status is a cheap blood test.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer, Trials enrol too few, too slowly, Triple-negative breast cancer (TNBC).
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer.
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer, Trials enrol too few, too slowly.